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Abstract Monocyte chemoattractant protein-1 (MCP-1) is a
member of the L chemokine family which acts through specific
seven transmembrane receptors to recruit monocytes, basophils,
and T lymphocytes to sites of inflammation. To identify regions
of the human MCP-1 protein which are important for its
biological activity, we have synthesized domain-specific peptides
and tested their ability to antagonize MCP-1 binding and
chemotaxis in THP-1 cells. We have found that an intercysteine
first loop peptide encompassing amino acids 13^35 inhibits
MCP-1 binding and chemotactic activity, while peptides
representing the amino-terminus (amino acids 1^10), second
loop (amino acids 37^51), and carboxy-terminus (amino acids
56^71) of MCP-1 have no effect. In addition, we have found that
cyclization of the first loop peptide by disulfide linkage and
blocking the C-terminus of the peptide by amidation increases
the activity of this peptide to block MCP-1 binding and
chemotaxis. In order to specifically identify amino acid residues
within the first loop that are crucial for MCP-1 functional
activity, we have substituted alanine for tyrosine (Y13A) or
arginine (R18A) in MCP-1 recombinant proteins. While
baculovirus produced wild type and R18A MCP-1 proteins are
indistinguishable in their ability to induce THP-1 chemotaxis and
show modest effects in binding activity compared to commer-
cially available recombinant MCP-1 protein, the Y13A point
mutation causes a dramatic loss in function. The identification of
functional domains of MCP-1 will assist in the design of MCP-1
receptor antagonists which may be clinically beneficial in a
number of inflammatory diseases.
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1. Introduction
Monocyte chemoattractant protein-1 (MCP-1) belongs to a
family of low molecular weight proteins collectively called
chemokines, which mediate the recruitment of speci¢c subsets
of leukocytes including monocytes and lymphocytes into in-
£ammatory sites [1^3]. Chemokines are chemoattractant cyto-
kines which are separated into four subfamilies based on the
arrangement of two N-terminal conserved cysteines (for re-
views, see [4^11]). The K or CXC subfamily includes such
proteins as IL-8 and NAP-2 and is characterized by a single
residue separating the two N-terminal conserved cysteines.
The L or CC chemokine subfamily includes MCP-1, -2, -3,
-4, and -5, eotaxin, RANTES, and MIP-1K and L which have
their N-terminal cysteines located adjacent to each other. The
third, Q or C subfamily has a single cysteine at this position
and is represented by lymphotactin as its sole member [12].
The most recently identi¢ed subfamily is a class of membrane
bound chemokines which express a CX3C motif [13]. In ad-
dition to structural di¡erences, chemokines subfamilies dis-
play di¡erential activities for leukocyte subsets. The CXC
chemokines preferentially attract neutrophils while the CC
chemokines are chemotactic for monocytes, memory T cells,
and basophils. Lymphotactin, on the other hand, is a chemo-
attractant for CD43/CD83 T cells. The activity of the chemo-
kines for speci¢c subsets of leukocytes is maintained within
each subfamily and the fact that each subfamily maps to
separate chromosomes [14] suggests that chemokine structure
and genetics may contribute to their leukocyte selectivity.
Although the chromosomal location of human MCP-1 on
chromosome 17 [15] has not yet been correlated with any
genetic diseases, the activity of MCP-1 in inducing monocyte
in¢ltration implies its role in several in£ammatory diseases
such as rheumatoid arthritis [16,17], atherosclerosis [18^20],
and in£ammatory bowel disease [21]. Its potential role in these
disease processes has led several laboratories to study MCP-1
structure-function relationships with the hope that this infor-
mation may lead to the development of therapeutic modula-
tors of in£ammatory diseases. The three-dimensional structure
of MCP-1 by NMR analysis and its structural homology to
MIP-1L [22,23] indicate that MCP-1 contains a long, £exible
N-terminus followed by three antiparallel L sheets over which
the C-terminal K-helix rests. Deletion or mutational analysis
of MCP-1 suggests that the N-terminal residues of this chemo-
kine are important for receptor binding and chemotaxis
(Table 1). This region, however, does not appear to be su⁄-
cient for activity since N-terminal peptides containing residues
1^10 are also inactive [24,25]. Additionally, the L sheet region
has been reported to be important for MCP-1 activity since
site-directed mutagenesis of residues Tyr28 and Arg30 results
in a loss of monocyte chemoattractant activity, while point
mutations in Thr10 and Tyr13 have greatly lowered activity
[25^27]. Further support for the importance of the N-terminal
region includes the ¢nding that high concentrations of syn-
thetic peptides encompassing amino acids 13^35 of MCP-1
stimulate monocyte migration and competitively inhibit the
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binding of native MCP-1 to peripheral blood monocytes [28].
The functional role of the carboxy-terminal tail of MCP-1
remains uncertain though it has been proposed that this re-
gion may be required for full chemoattractant potency of the
protein [25,27,28].
In this study we determined the activity of MCP-1 domains
using a combination of domain-speci¢c peptides and site-di-
rected mutagenesis. We have analyzed the ability of synthetic
peptides to compete with radiolabeled MCP-1 for binding to
its receptor on monomyelocytic THP-1 cell, and correlated
these activities to e¡ects on MCP-1-mediated THP-1 cell mi-
gration. These studies allow us to conclude that the ¢rst loop
of MCP-1 is necessary for receptor binding and migratory
activity but it alone is not su⁄cient for full agonist activity
that is seen in the native chemokine.
2. Materials and methods
2.1. Reagents
MCP-1 and MCP-3 were purchased from RpD Systems (Minneap-
olis, MN). 125I-labeled (2200 Ci/mmol) recombinant human MCP-1
and [3H]thymidine (6.7 Ci/mmol) were from Dupont NEN (Wilming-
ton, DE), and chemicals were obtained from Sigma (St. Louis, MO).
2.2. Cells
The THP-1 monocytic cell line was purchased from American Type
Tissue Culture (Rockville, MD) and grown in RPMI medium (JRH
Biosciences, Lenexa, KS) containing 10% fetal calf serum (FCS; Gem-
ini Products Inc., Calabasas, CA), 2 mM glutamine (BioWhittaker,
Walkersville, MD), 100 units/ml penicillin and 100 units/ml strepto-
mycin (Irvine Scienti¢c, Santa Ana, CA). Cells were incubated at
37‡C, 5% CO2 under humid conditions.
2.3. MCP-1 binding assay
To measure the ability of MCP-1, MCP-3, and FLAG-tagged MCP
fusion proteins to bind THP-1 cell surface receptors, 1 Wm glass ¢ber
¢lter plates (Millipore, Bedford, MA) were coated overnight at 4‡C
with 0.1% polyethylamine, 2% bovine serum albumin (Intergen, Pur-
chase, NY) w/v in water. Peptides or FLAG-tagged proteins were
added to each well at the indicated concentrations. 125I-MCP-1 and
THP-1 cells diluted in 50 mM HEPES, pH 7.2, 1 mM CaCl2, 5 mM
MgCl2, 0.5% ovalbumin were then added to a ¢nal concentration of
0.25 nM and 1.3U106 cells per well, respectively. After 45 min incu-
bation at room temperature, the plates were washed with 10 mM
HEPES, pH 7.2, 0.5 M NaCl, and 0.5% ovalbumin and counted on
a Wallac Microbeta plate reader (Gaithersburg, MD).
2.4. MCP-1-mediated migration assay
The ability of wild type and mutant MCP-1 to mediate the migra-
tion of monocytic THP-1 cells through a ¢lter was measured with and
without the addition of potential peptide antagonists. 96-transwell
5 Wm ¢lter plates (Neuroprobe, Cabin John, MD) were coated over-
night at 4‡C with 0.12 Wg/well human ¢bronectin derived from whole
plasma in phosphate bu¡ered saline (PBS). THP-1 cells were labeled
with 1 mCi/ml [3H]thymidine in RPMI-10% FCS at 37‡C overnight.
After labeling, the cells were washed in human serum albumin (Inter-
gen)-DME (Irvine Scienti¢c) and adjusted to a density of 1U107 cells/
ml. For peptide antagonist studies, 1.5U105 THP-1 cells were incu-
bated with the indicated concentrations of peptides 5 min prior to
transfer of cells to the transwell plates. Either 6 nM recombinant
human MCP-1 or MCP-3 was added to the bottom of the ¢lter plate,
and migration was allowed to proceed for 2 h at 37‡C. After this time,
the number of labeled cells which had migrated into the lower com-
partment was measured on a Wallac Microbeta plate reader. For
MCP-1 mutant analysis, puri¢ed FLAG-tagged MCP-1 proteins re-
placed the commercial MCP-1/MCP-3.
2.5. Peptide synthesis
Amino acid precursors were purchased from Bachem (Torrance,
CA). Synthetic peptides were prepared on a System 990 automated
peptide synthesizer (Beckman Instruments, Inc., Palo Alto, CA) using
t-butoxycarbonyl methodology following the standardized cycle [29].
Cyclized peptides were formed by the iodine method [30]. Peptides
were puri¢ed on a Waters Delta Prep 3000 high performance liquid
chromatography system with a C18 column (RPC18 Ultrasphere,
5 mm, 4.6U150 mm inner diameter) and sent to Beckman Research
Institute of the City of Hope (Duarte, CA) for FAB mass spectral
analysis. Tables 3 and 4 list the peptides used in these studies. Abbre-
viations have been used to replace the actual amino acid sequences in
Fig. 2 and are as follows:
C-¢rst loop: AC*YNFTNRKISVQRLASYRRITSSKC*-NH2
second loop: PKEAVIFKTIVAKEI
2.6. MCP-1 cloning
Total RNA was isolated from human umbilical vein endothelial
cells using RNAzol B following the manufacturer instructions (Bio-
Tec, Houston, TX). 1 Wg of total RNA was used to prepare MCP-1
cDNA by reverse transcriptase and polymerase chain reaction using
the GeneAmp RNA PCR kit (Perkin-Elmer, Norwalk, CT) with the
following primers: 5P-GGATCCATGAAAGTCTCTGCCGCCCT-
TCTGT-3P ; 5P-GGATCCTCAAGTCTTCGGAGTTTGGGTTTGC-
3P. The resultant PCR fragment was subcloned into the plasmid
pCR 2.1 using the TA Cloning Kit (Invitrogen, San Diego, CA) to
create pTAMCP-1. FLAG peptide fusion subclones were created by
performing PCR using Pfu and pTAMCP-1 following the instructions
of the manufacturer (Stratagene, La Jolla, CA) with the following
primers (FLAG peptide sequence is underlined): 5P-AGCG-
GATCCTCACTTGTCATCGTCGTCCTTGTAGTCCCCTCCAGT-
CTTCGGAGTTTGGGTTTGCTT-3P ; 5P-GGATCCATGAAAGTC-
TCTGCCGCCCTTCTGT-3P. The resulting products were cloned
into pCRScript (Stratagene). Restriction fragments were subcloned
into pBlueBac III (Invitrogen, San Diego, CA) yielding the plasmids
pBB3MCP1FLAG, pBB3Y13AFLAG, and pBB3R18AFLAG. All
clones were veri¢ed by DNA sequence analysis using Sequenase
(Amersham/USB, Cleveland, OH).
2.7. Site-directed mutagenesis
Site-speci¢c mutagenesis was performed according to the methods
of Kunkel et al. [31]. Codon Y13 of human MCP-1 was mutated to
encode alanine using the following oligonucleotide (underlined bases
indicate change from wild type): 5P-GGTGAAGTTAGCGCAG-
CAGGT-3P. Codon R18 was mutated to encode alanine using the
following oligonucleotide (underlined bases indicated change from
wild type): 5P-TGAGATCTTCGCATTGGTGAA-3P. Oligonucleo-
tides were synthesized on an ABI 381A DNA synthesizer (Applied
Biosystems, Foster City, CA). Clone identi¢cation was veri¢ed by
restriction digest and DNA sequence analysis using Sequenase (Amer-
sham/USB, Cleveland, OH).
2.8. Baculovirus and protein production
Baculovirus were generated in Sf9 cells using the FLAG fusion
plasmid constructs described previously with the Bac-N-Blue trans-
fection kit (Invitrogen). Viral isolates were plaque puri¢ed and ampli-
¢ed according to the manufacturer’s instructions. MCP-1 producing
isolates were identi¢ed by performing ELISA on culture supernatants
with the Quantikine Human MCP-1 Immunoassay (RpD Systems,
Minneapolis, MN).
Spinner cultures of log phase Sf9 cells were infected with virus stock
for 10 days. Cell debris and virus particles were removed by centrifu-
gation at 67 000Ug for 1 h, and MCP-1 wild type and mutant FLAG-
tagged recombinant proteins were isolated from Sf9 cell supernatants
as follows. 250 ml of baculovirus supernatant containing between
0.4 and 2 Wg/ml FLAG fusion protein were a⁄nity puri¢ed over a
5 ml Anti-FLAG M2 A⁄nity Gel (Eastman Kodak Company, New
Haven, CT) column as recommended by Kodak. Fractions were as-
sayed for MCP-1 content by the Quantikine Human MCP-1 Immuno-
assay, and positive fractions were pooled. The pooled fractions were
then quantitated again and analyzed for purity by Coomassie protein
staining and MCP-1 immunoblotting.
2.9. MCP-1 immunoblots
To verify that MCP-1 quantitation was accurate, commercial and
FLAG-tagged MCP-1 recombinant proteins were analyzed by immuo-
blotting with MCP-1-speci¢c antibodies. Equal amounts of commer-
cial and FLAG-tagged MCP-1 proteins were resolved through a 14%
SDS-polyacrylamide gel and transferred to nitrocellulose (Micron
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Separations, Westboro, MA) using standard procedures. The nitro-
cellulose was then blocked with 5% non-fat milk in PBS for 1 hour
followed by incubation with horseradish peroxidase-conjugated MCP-
1 antibodies (RpD Systems, Minneapolis, MN). After washing with
PBS, blots were developed using the enhanced chemiluminescent sys-
tem (ECL; Amersham, Arlington Heights, IL) and autoradiography.
3. Results
3.1. MCP-1-mediated chemotaxis
To determine the activity of wild type or mutant MCP-1
constructs, a 96 well transwell migration assay was estab-
lished. The activity of MCP-1 and MCP-3, two chemokines
known to bind to the L chemokine receptor CCR2b [32], was
measured. Under the conditions described in Section 2, we
have demonstrated that MCP-1 or MCP-3 chemokines can
equally promote the chemotaxis of monocytic THP-1 cells
(Fig. 1). As reported [24], THP-1 cell migration mediated by
these chemokines is concentration-dependent such that it
reaches a maximum response at 1037 nM then declines at
higher concentrations. To determine if the assay measured
chemotaxis, we evaluated whether migration was dependent
on a concentration gradient by carrying out a checkerboard
analysis. Table 2 demonstrates that fewer cells migrated as the
concentration of MCP-1 was increased in the upper compart-
ment. In contrast, when equal concentrations of MCP-1 were
generated in both the upper and lower compartment there was
no net movement of cells. Taken together, these results estab-
lish that our experimental conditions are re£ective of MCP-1-
mediated activities as previously cited [25].
3.2. Functional activity of MCP-1 domains
To determine which domains of MCP-1 were important for
receptor binding and chemotactic activity, synthetic peptides
derived from the amino-terminus, ¢rst loop, second loop, and
carboxy-terminus of MCP-1 were tested for their ability to
inhibit 125I-MCP-1 binding and chemotaxis. As presented in
Table 3, peptides derived from the ¢rst loop blocked the bind-
ing of 125I MCP-1 to THP-1 cells with an estimated IC50 of 32
WM. Additionally, the ¢rst loop peptide weakly inhibited
MCP-1-induced cell migration with an IC50 of 633 WM. In
contrast, no inhibitory activity was observed from peptides
derived from the N- or C-terminus or the second loop. To
determine if potency of the peptides could be enhanced, two
¢rst loop peptides were synthesized and cyclized by disul¢de
linkage via the cysteine residues. Table 4 shows that the ac-
tivity of the ¢rst loop peptides in these assays was increased
53^71% by cyclization and amidation.
As demonstrated in Fig. 2A, ¢rst loop cyclic peptides
blocked the binding of 125I-MCP-1 to THP-1 cells in a
dose-dependent manner while a peptide derived from the sec-
ond loop did not. The estimated IC50 of the cyclic peptide is
15 WM. Next we evaluated whether the cyclic peptide could
inhibit MCP-1-directed migration. In this experiment, labeled
THP-1 cells were preincubated with or without peptide antag-
onists for 5 min and then placed in the upper compartment of
a transwell ¢lter plate. 6 nM MCP-1 was placed in the lower
compartment and the ability of MCP-1 to mediate the migra-
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Table 2
THP-1 cell migration in response to MCP-1 is dependent on a concentration gradient
Lower chamber (ng/ml) Upper chamber (ng/ml)
0 CPM 10 CPM 20 CPM 50 CPM
0 265 þ 46 179 þ 41 142 þ 23 133 þ 60
10 710 þ 159 311 þ 64 151 þ 15 191 þ 67
20 877 þ 141 448 þ 58 220 þ 79 132 þ 31
50 638 þ 163 598 þ 62 334 þ 58 86 þ 15
Indicated concentrations of MCP-1 were placed in the lower and upper compartments of a 96 well transwell plate and migration of 1.5U105 THP-1
cells was evaluated following a 2 h, 37‡C incubation. This table represents one of a minimum of two independent experiments. Mean CPM þ S.D.
are shown (n = 4).
Fig. 1. Chemotactic activity of MCP-1 and MCP-3. The ability of
MCP-1 and MCP-3 to induce migration of THP-1 monocytic cells
was measured as described in Section 2. 1.5U105 [3H]thymidine-la-
beled THP-1 cells were placed in the upper compartment of a 5 Wm
transwell plate, and allowed to migrate for 2 h at 37‡C in response
to the indicated concentrations of either MCP-1 or MCP-3. This ¢g-
ure represents one of a minimum of two independent experiments
(mean CPM þ S.D. are shown, n = 4).
Table 1
MCP-1 sequence
N-terminus First loop Second loop
Q1PDAINAPVT10 CCYNFTNRKISVQRLASYRRITSSK35 CPKEAVIFKTIVAKEI51C
C-terminus
A53DPKQKWVQDSMDHLDKQTQTPKT76
The human MCP-1 sequence as described by Yoshimura et al. [33]. The tertiary structure indicated is based on structural homology of MCP-1 with
MIP-1L [23].
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tion of the labeled THP-1 cells in the presence of these pep-
tides was measured. The ¢rst loop cyclic peptide demonstrated
a dose-dependent inhibition of MCP-1-mediated THP-1 cell
migration, whereas the second loop peptide had little e¡ect.
These results suggest that binding and migration inhibitory
activity is localized to the ¢rst loop of MCP-1. However, it
is clear that the activity of the peptide is signi¢cantly reduced
compared to native MCP-1 (see Fig. 4). In addition, the ¢rst
loop of MCP-1 does not appear to be su⁄cient for migration
activity since the cyclic peptide alone fails to promote THP-1
chemotaxis (data not shown).
3.3. Site-directed mutagenesis of tyrosine 13 and arginine 18 of
MCP-1
Since the activities of the MCP-1 peptides suggest that the
chemotactic activity of native MCP-1 resides primarily in the
¢rst loop, amino acids within this region, which are predicted
to be solvent exposed and therefore potentially available for
receptor interactions, were chosen for mutagenesis [22]. Resi-
dues tyrosine 13 and arginine 18 were converted to alanine by
site-directed mutagenesis and full length mutant recombinant
MCP-1 proteins were generated.
Previous reports have demonstrated that the addition of a
FLAG epitope to the carboxy-terminus of MCP-1 would not
signi¢cantly alter its activity [25]. We chose to fuse the FLAG
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Table 4
Activity of cyclized ¢rst loop peptides
Sequence Binding Migration
IC50 (WM) IC50 (WM)
AYNFTNRKISVQRLASYRRITSSK 32 633
AC*YNFTNRKISVQRLASYRRITSSKC* 16 401
AC*YNFTNRKISVQRLASYRRITSSKC*-NH2 15 186
The e¡ect of peptide cyclization was measured as described in Section 2and Table 3. The IC50s shown represent an average of a minimum of two
independent experiments (n = 4). For chemical stability, an alanine was used in replacement of C11 and C12.
Fig. 2. Inhibition of MCP-1 binding and chemotaxis by a cyclized
¢rst loop peptide. Titration of cyclized ¢rst (C-1st Loop) versus the
second (2nd Loop) loop peptides in inhibiting 125I-MCP-1 binding
to THP-1 cells (A) or MCP-1-directed migration (B) was done using
methods described in Section 2 and Table 3. Each data point repre-
sents the mean CPM þ S.D. of four replicates from one of a mini-
mum of two independent experiments.
Fig. 3. Recombinant protein analysis of a⁄nity puri¢ed FLAG-
tagged MCP-1 recombinant proteins. FLAG-tagged mutant and
wild type proteins were expressed using the baculovirus system and
a⁄nity puri¢ed over an anti-FLAG antibody column. Pooled wild
type (WT), mutant (R18A, Y13A), or commercial (RpD) recombi-
nant protein were resolved through a 14% polyacrylamide gel and
either stained with Coomassie blue (A) or immunoblotted with
MCP-1-speci¢c antibodies (B).
Table 3
Binding and migration inhibitory activity is present in the ¢rst loop
Sequence Domain Binding Migration
IC50 (WM) IC50 (WM)
QPDAINAPVTA N-terminus s 300 s 1000
AYNFTNRKISVQRLASYRRITSSK First loop 32 633
PKEAVIFKTIVAKEI Second loop s 300 s 1000
KQKWVQDSMDHLDKQT C-terminus s 300 s 1000
For binding studies, a total of 1.3U106 THP-1 cells were mixed with or without serial dilutions of synthetic peptides and 0.25 nM 125I-MCP-1 for
45 min at room temperature. For MCP-1-mediated chemotaxis, 1.5U105 [3H]thymidine-labeled THP-1 cells were preincubated with or without
serial dilutions of peptide and placed in the upper chamber. Cells which had successfully migrated to the lower chamber were counted and
expressed as mean CPM þ SD (n = 4). IC50s were calculated from peptide serial dilutions using the CurFit program (Interactive Microware,
Inc., State College, PA) (n = 4), and the data represent an average of a minimum of two independent experiments. For chemical stability, an
alanine was used to replace residue C11.
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epitope to MCP-1 wild type and mutant proteins for assist-
ance in protein identi¢cation and puri¢cation. Since mainte-
nance of biological activity of these proteins was crucial for
our studies, the proteins were expressed in the eukaryotic
baculovirus insect cell. FLAG-tagged mutants and wild type
MCP-1 were puri¢ed from Sf9 cell supernatants using an anti-
FLAG antibody column. Peak fractions were quanti¢ed for
MCP-1 content using a MCP-1 immunoassay, then qualita-
tively evaluated by an MCP-1 immunoblot (Fig. 3A) and
Coomassie stained polyacrylamide gel (Fig. 3B). A prominent
band is observed with an estimated molecular mass of 10 kDa
which is in close agreement with the predicted molecular
weight of 8.7 kDa for MCP-1 plus the 1 kDA FLAG epitope
[33].
The puri¢ed mutant and wild type proteins were then eval-
uated for their ability to compete for 125I-MCP-1 binding to
THP-1 cells (Fig. 4) and to mediate THP-1 chemotaxis in the
transwell migration assay (Fig. 5). Both the wild type and
R18A MCP-1 FLAG-tagged recombinant proteins demon-
strated similar activity in the binding assay, although they
varied slightly from the non-tagged commercial MCP-1 re-
combinant protein. Their similar activities in the binding as-
say were paralleled in the migration assay where only slight
di¡erences between commercial, wild type, and R18A mutant
MCP-1 proteins were detected. In contrast, the Y13A mutant
MCP-1 recombinant protein was less e¡ective in competing
with 125I-MCP-1 binding to THP-1 cells. In agreement with
the binding data, Y13A demonstrated no signi¢cant chemo-
tactic activity in the migration assay. Thus, our data supports
those of Beall et al. who reported that tyrosine 13 is a critical
residue for MCP-1 biological activity [27].
4. Discussion
The study of L chemokines and their receptors has gener-
ated great interest due to their strong correlation with several disease processes including in£ammation and human immu-
node¢ciency virus-1 cell entry and replication [34,35]. Since an
inhibitor of these molecules may be clinically important, we
are investigating which amino acid residues or domains are
required for receptor binding and cell signaling. In this study
we have determined the activity of MCP-1 domains using a
combination of domain-speci¢c peptides and site-directed mu-
tagenesis. We have shown that synthetic peptides from the
¢rst loop of MCP-1, and not the second loop, N-terminus,
or C-terminus, could compete with radiolabeled MCP-1 for
binding to its receptor on THP-1 cells. This activity correlated
with a parallel loss in MCP-1-mediated THP-1 cell migration.
To substantiate our ¢ndings, we chose speci¢c amino acids
within the ¢rst loop for site-directed mutagenesis, and found
that a substitution of tyrosine 13 with an alanine signi¢cantly
altered MCP-1 receptor binding and chemotactic activity
while a substitution of arginine 18 for alanine had no e¡ect.
NMR analysis of MCP-1 reveals high structural homology
to MIP-1L [23,36]. The three dimensional conformation in-
cludes a long, £exible N-terminus leading to three anti-parallel
L sheets followed by a carboxy-terminal K helix. Previous
reports have provided evidence for a role of the N-terminal
tail in proper signaling activity [24]. However, the mechanism
by which N-terminal deletions or mutations alter MCP-1 ac-
tivity is still controversial. Some groups propose that the N-
terminus is essential for MCP-1 dimer formation, and it is the
homodimer which binds and activates the MCP-1 cell surface
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Fig. 4. FLAG-tagged wild type and mutant MCP-1 binding to
THP-1 cells. A⁄nity puri¢ed FLAG-tagged wild type (WT), mutant
(R18A, Y13A), and commercial (RpD) recombinant proteins were
tested for their ability to compete with 125I-MCP-1 binding to THP-
1 cells. The indicated concentrations of recombinant protein were
co-incubated with 0.25 nM 125I-MCP-1 and 1.3U106 THP-1 cells
for 45 min at room temperature. After washing the cells of un-
bound MCP-1, cell bound 125I-MCP-1 was measured by counting
on a Wallac Microbeta plate reader and expressed as the mean
CPM þ S.D. (n = 4). This ¢gure is a representative experiment from
three independent experiments.
Fig. 5. FLAG-tagged wild type and mutant MCP-1 mediated migra-
tion of THP-1 cells. A⁄nity puri¢ed FLAG-tagged R18A mutant
and commercial (RpD) (A), and wild type (WT), and Y13A mutant
(B) were evaluated for their ability to promote THP-1 migration as
described in Section 2 and Fig. 1. This ¢gure is a single representa-
tive experiment from three independent experiments (n = 4).
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receptor CCR2b while opposing reports suggest dimerization
does not occur at physiological concentrations and is thus not
a component of receptor activation, leading one to question
whether the N-terminal domain directly binds to CCR2b
[37,38]. Studies performed by Gong and Clark-Lewis [24]
identi¢ed critical N-terminal residues through synthetic mod-
i¢cation or deletion. In these studies, the backbone structure
of the N-terminal amino acid located at position 1, or chem-
ical modi¢cation of this residue results in disruption of recep-
tor binding and activity. Furthermore, most N-terminal dele-
tion mutants lack monocyte chemoattractant activity as well
as THP-1 calcium mobilization [24,39]. In agreement with
published reports [24,39], we have found that peptides con-
taining residues 1^10 from the amino-terminus of MCP-1 lack
biological activity.
The C-terminal K-helix has not been convincingly shown to
play a role in MCP-1 receptor binding and chemotactic activ-
ity. As presented in this study, C-terminal peptides do not
inhibit binding or migration. Similarly, Beall et al. found
that C-terminal point mutations had no e¡ect on MCP-1
chemotactic activity. Alternatively, Zhang et al. [25] report
that this region may not be a direct regulator of signaling,
but suggest that modi¢cation of this site decreases MCP-1’s
chemoattractant potency. In all, these results do not support a
functional requirement for the C-terminal alpha helix of
MCP-1 although extensive deletions or alterations in this re-
gion may reduce the potency of MCP-1.
In contrast, the ¢rst loop of MCP-1 is gaining increased
attention. For example, early work by Valente et al. [28]
showed that synthetic peptides encompassing the ¢rst inter-
cysteine loop amino acids 13^35 stimulated monocyte migra-
tion and competed with native MCP-1 for binding, suggesting
this region may contain the most critical residues for MCP-1
activity. In this report we provide data that peptides from the
¢rst loop (amino acids 13^35) of human MCP-1 can compete
for THP-1 receptor binding and chemotactic activity, while
the amino-terminal, second loop (amino acids 37^51) and
carboxy-terminal (amino acids 56^73) domains alone are not
su⁄cient for biological activity. Furthermore, the potency of
the ¢rst loop peptide can be increased by cyclization and
amidation. It should be noted that intact MCP-1 binds and
promotes migration with low nanomolar potency while micro-
molar concentrations of the cyclic ¢rst loop peptides are re-
quired to block binding and migration, suggesting that other
regions of the molecule contribute to its full activity. Cur-
rently, we do not fully understand why the concentration of
peptide required to block 125I-MCP-1 binding to cells di¡ers
from the concentration required for blocking MCP-1 induced
migration. However, it should be noted that the concentration
of MCP-1 used in the two assays di¡er by V25-fold, that is,
0.25 nM and 6 nM were used for the binding and migration
assays, respectively. Therefore the molar ratio of peptide to
ligand is V115 000:1 for both assays. The speci¢city of the
peptides was demonstrated by the fact that THP-1 cell migra-
tion in response to RANTES or neutrophil migration in re-
sponse to FMLP was not blocked by the peptides (data not
shown).
Residues from the second L strand (termed L1) have been
implicated as important regions for MCP-1 activity. Beall et
al. have presented evidence that MCP-1 proteins with two
point mutations in the L1 strand at positions Y28, and R30
have greatly reduced or completely absent chemotactic activ-
ity [26,27]. However, Zhang et al. have shown that single
amino acid changes in R24, Y28, and R30 resulted in MCP-
1 proteins without chemoattractant activity, while point mu-
tations at position 27 had only a slight e¡ect [25].
To speci¢cally identify critical amino acid residues, FLAG-
tagged ¢rst loop MCP-1 mutants were made and expressed in
a eukaryotic insect cell system. We have shown that wild type
and R18A MCP-1 FLAG-tagged proteins mediate the migra-
tion of THP-1 cells at similar concentrations as commercial
recombinant MCP-1 protein. In contrast, the substitution of
tyrosine 13 with an alanine (Y13A) caused almost complete
loss of MCP-1 activity even at the highest concentrations
tested. The importance of tyrosine 13 in MCP-1 biological
activity has recently been reported by Beall et al. in which
replacement of tyrosine 13 with an isoleucine diminished
MCP-1’s ability to promote monocyte chemotaxis and raise
intracellular calcium levels [27]. This loss of chemotactic
activity is correlated with a decrease in the ability of
the protein to compete with native MCP-1 for receptor
binding. The reduction of MCP-1 functional activity may be
due to a conformational change in the MCP-1 protein
such that the binding site, whether it be at position 13 or
elsewhere, is not available to interact with CCR2b. Conserva-
tion of the aromatic side chain at position 13 by substitution
of tyrosine to phenylalanine does not reduce MCP-1 activity
[39] suggesting aromatic side chains may be essential for
activity. NMR analysis of these mutants would assist our
understanding of whether a conformational change has oc-
curred.
NMR data predict that the dimer interface of CC chemo-
kines is formed by the N-terminal L-sheet of the protein,
whereas with CXC chemokines the second beta strand is in-
volved in dimer formation [23,40]. Therefore, if MCP-1
dimers are required for binding and the Tyr13 residue is in-
volved in dimer formation, substitution of the Tyr13 could
lead to a loss of dimer formation and subsequent binding.
Alternatively, the tyrosine 13 residue may be part of the bind-
ing site such that it is an absolute requirement for receptor
binding.
Two major MCP-1 receptors have been identi¢ed (CCR2a
and CCR2b) which di¡er in their cytoplasmic tails [41]. Like
C5a, it has been proposed that MCP-1 binds to CCR2b
through a two step mechanism [42,43]. In this two step model,
MCP-1 ¢rst binds to the amino-terminal of the CCR2b re-
ceptor via a high a⁄nity binding site. This interaction induces
a conformational change in the receptor, such that a £exible
region of MCP-1 binds to the lower a⁄nity signaling site
which is thought to be contained within the extracellular loops
of the receptor. If this hypothesis is correct, then it is logical
that there are several sites on MCP-1 which are critical for
receptor activation. Since inhibition of low a⁄nity interac-
tions may not be measurable in our experimental conditions,
we propose that the intercysteine ¢rst loop is critical for re-
ceptor interactions at the high a⁄nity site. Preliminary data
from our laboratory suggests that the cyclic ¢rst loop peptide
can bind directly to the N-terminus of CCR2b (data not
shown). If the high a⁄nity interaction is the critical ¢rst
step in MCP-1-CCR2b interactions, then it is tempting to
speculate that potent antagonists to this site would be novel
therapeutic agents for a variety of diseases characterized by
lymphocyte and monocyte in¢ltration. In summary, we pro-
vide evidence using two distinct experimental approaches that
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the ¢rst loop of MCP-1 is important for binding and chemo-
tactic activity.
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